Repeated Low-Level Red Light Therapy

Uses

How it works

Dosage & preparation

Evidence quality

Highlighted claims

• The RAMP trial tests whether RLRL therapy can improve choroidal microcirculation and delay progression of atrophic fundus lesions in adults with pathologic myopia. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
• RLRL has evidence for controlling myopia progression in children, but it had not previously been reported for pathologic myopia. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
• RLRL uses red-light wavelengths around 650 nm and is described as non-invasive and operationally simple. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
• The active intervention uses 660 nm light at 65 mW/cm² twice daily for 3 minutes, 5 days per week, over 12 months. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial
• The proposed RLRL mechanism in myopia control involves stimulation of mitochondrial function in the retinal pigment epithelium and choroid. — LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial